Abstract Number: 2670 • ACR Convergence 2025
Real-World Experience of Anifrolumab in 24 Patients with Refractory Dermatomyositis: A Multicenter Retrospective Study.
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease marked by muscle weakness and characteristic cutaneous manifestations. Dysregulation of the Type I interferon (IFN-I) pathway plays…Abstract Number: 2055 • ACR Convergence 2025
Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis
Background/Purpose: Total Improvement Score (TIS), as defined by the ACR/EULAR myositis response criteria, is increasingly employed as a primary endpoint in clinical trials for dermatomyositis…Abstract Number: 1208 • ACR Convergence 2025
Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Background/Purpose: Juvenile dermatomyositis (JDM) is an inflammatory vasculopathy characterized by muscle weakness and systemic inflammation. This study aimed to investigate the clinical utility of neutrophil…Abstract Number: 0290 • ACR Convergence 2025
Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…Abstract Number: 2669 • ACR Convergence 2025
RESET-Myositis: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), A Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Idiopathic Inflammatory Myopathies
Background/Purpose: The goals of treatment for idiopathic inflammatory myopathy (IIM) are to eliminate or reduce inflammation, restore muscle performance, reduce morbidity, and improve a patient’s…Abstract Number: 2053 • ACR Convergence 2025
A Prospective Study Unveils Damage Accrual and Myositis Specific Antibodies as Key Risk Factors for Mortality in Myositis
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by muscular inflammation that can affect any organ or system. Reported mortality rates…Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…Abstract Number: 0287 • ACR Convergence 2025
Comprehensive Profiling of Neutrophil Subsets Reveals Functional Signatures Linked to Vasculopathic Features in Patients with Inflammatory Myopathies
Background/Purpose: Vasculopathic manifestations of idiopathic inflammatory myopathies (IIM) such as interstitial lung disease (ILD), calcinosis, skin ulcers, mechanic’s hands, are characterized by immune-mediated vascular damage.…Abstract Number: 2668 • ACR Convergence 2025
CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit
Background/Purpose: Inflammatory skin diseases vary widely in symptoms and causes. While ultraviolet (UV) light helps treat some like vitiligo and psoriasis, in conditions like cutaneous…Abstract Number: 1967 • ACR Convergence 2025
Developing an Algorithm to Quantify Dermatomyositis-Associated Calcinosis Using Infrared Imaging
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by chronic muscle and skin inflammation. One potential complication of DM is calcinosis, the heterotopic calcification…Abstract Number: 1202 • ACR Convergence 2025
High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of idiopathic inflammatory myopathies (IIM), adversely impacting clinical outcomes. While the ACR/CHEST guideline recommends…Abstract Number: 0286 • ACR Convergence 2025
Anifrolumab For Treatment Of Refractory Juvenile Dermatomyositis In Adult Patients
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune connective tissue disorder with a chronic, relapsing course that can persist into adulthood. Current therapies exhibit widely variable…Abstract Number: 2558 • ACR Convergence 2025
Impact of Social Determinants of Health on Patient Perceptions of Home Infusion Therapy in the Treatment of Rheumatologic Conditions
Background/Purpose: Home infusion therapy is an established alternative site of care for patients requiring administration of infusion medications through a needle or catheter. Supported by…Abstract Number: 1956 • ACR Convergence 2025
68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in MDA5 dermatomyositis (MDA5-DM). Fibrosis and inflammation are pivotal drivers in the pathogenesis of…Abstract Number: 1200 • ACR Convergence 2025
Mortality in Idiopathic Inflammatory Myopathy in the Toulouse cohort (MIIRTALITY)
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are a group of heterogeneous connective tissue diseases including dermatomyositis (DM), polymyositis (PM), anti-synthetase syndromes (ASS), immune-mediated necrotizing myopathies (NM),…
- 1
- 2
- 3
- …
- 28
- Next Page »